Overview

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

Status:
RECRUITING

Trial end date:
2028-04-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.

Phase:

PHASE1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

amivantamab
Carboplatin
Paclitaxel
pembrolizumab